Brexpiprazole (Rexulti) is effective for treating agitation associated with Alzheimer's dementia (AAD), but appears to carry the increased risk for death observed with other antipsychotics in elderly ...
FDA advisors voted in favor of brexpiprazole (Rexulti) for treating agitation associated with Alzheimer's dementia (AAD), despite increased mortality risk. By a vote of 9-1 on Friday, members of the ...
In a randomized clinical trial, researchers determined whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation in patients with Alzheimer dementia. Brexpiprazole, 2 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with agitation in Alzheimer’s dementia were ...
For many people living with dementia and their caregivers, the worst symptom of the disease is not memory loss, but agitation. Whether it comes out as verbal insults or physical violence, agitation in ...
The US Food and Drug Administration (FDA) has approved the antipsychotic brexpiprazole (Rexulti, Otsuka and Lundbeck) for agitation associated with Alzheimer's disease (AD), making it the first ...
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the ...
Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia. Alembic has received the Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results